STAT3 Relays a Differential Response to Melanoma-Associated NRAS Mutations

Melanoma patients carrying an oncogenic NRAS mutation represent 20% of all cases and present worse survival, relapse rate and therapy response than patients with wild type NRAS or with BRAF mutations. Nevertheless, no efficient targeted therapy has emerged so far for this group of patients in compar...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, James, Novak, Daniel, Sachpekidis, Christos, Utikal, Jochen, Larribère, Lionel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016650/
https://www.ncbi.nlm.nih.gov/pubmed/31906480
http://dx.doi.org/10.3390/cancers12010119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016650/
https://www.ncbi.nlm.nih.gov/pubmed/31906480
http://dx.doi.org/10.3390/cancers12010119

Ejemplares similares